Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) - Analysts at William Blair reduced their FY2025 earnings estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note issued to investors on Wednesday, March 12th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $0.82 for the year, down from their previous estimate of $0.83. William Blair has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares' current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares' FY2026 earnings at $1.05 EPS.
Separately, UBS Group raised their price objective on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, January 27th.
Get Our Latest Analysis on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 1.7 %
TLX traded down $0.30 on Friday, hitting $17.30. The company's stock had a trading volume of 20,997 shares, compared to its average volume of 27,443. The stock's 50 day simple moving average is $17.51. Telix Pharmaceuticals Limited American Depositary Shares has a 12 month low of $14.01 and a 12 month high of $30.36.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
